{"i": ["placebo - controlled", "bilastine", "placebo", "ammonium hydroxide", "histamine", "Bilastine", "matching placebo", "bilastine -", "acetonitrile containing ammonium formate"], "o": ["AEs", "AUC0 \u2013 t", "Exposure and accumulation", "PK", "diarrhea", "peak effect", "hematology , chemistry laboratory test , or 12 - lead ECG results", "bilastine PK parameters .", "psychomotor activity", "antihistamine activity", "stomatitis", "plasma concentration", "renal clearance ( CLr ).", "Bilastine concentrations", "DSST or SSS", "safe and well tolerated", "apparent volume of distribution ( Vd / F ); oral clearance ( CL / F ) from plasma", "mean \u00b1 SD of DSST and SSS", "histamine - induced wheal ( a ) and flare responses", "max and area under the plasma concentration - time curve ( AUC )]", "psychomotor activities ( change in DSST or SSS", "bioavailability of", "subjective psychomotor activity", "Psychomotor activities", "Plasma", "DSST and SSS", "Japanese plasma concentrations", "within - run percentages of nominal concentrations", "wheal and flare response", "wheal and flare areas", "Absolute oral bioavailability", "Age , Weight , Height , Albumin , Bilirubin , Aspartate transaminase , Alanine aminotransferase , Blood Urea Nitrogen , Alkaline Phosphatase and Serum Creatinine .", "bilastine PK parameters", "plasma bilastine concentration", "bilastine in plasma and urine", "vital signs ( axillary body temperature , supine blood pressure , and supine pulse rate ), resting 12 - lead ECGs", "bilastine clearance ( CL ), central volume of distribution ( Vc ), intercompartmental clearance ( Q ), peripheral volume of distribution ( Vp ), and ka .", "inhibition % for wheal and flare", "digit symbol substitution test ( DSST )", "eczema", "flare response", "cumulative percentage of unchanged drug excreted into the urine ( Ae %)", "PK , PD , safety , and tolerability", "symptoms and signs , vital signs , 12 - lead ECGs , and clinical laboratory tests", "AEs [ dizziness", "plasma concentrations", "rates of AEs", "subject death or other serious adverse events", "glossitis", "epistaxis", "Stanford sleepiness scale ( SSS )", "moderate gastroenteritis", "rates of adverse events ( AEs )", "PK parameters", "objective function", "rate of AEs or worsening of severity", "bilastine", "terminal elimination half - life", "standard clinical laboratory tests ( hematology , blood biochemistry , urinalysis", "bilastine plasma concentration", "wheal response", "PK , pharmacodynamics ( PD ), safety , and tolerability", "plasma bilastine concentrations", "pharmacokinetics , pharmacodynamics , and tolerability", "DSST score"]}